Cipla, a leading pharmaceutical company, announced on Wednesday that it has received final approval from the US Food and Drug Administration (USFDA) for its Lanreotide injection. This medication is indicated for the treatment of acromegaly, a hormonal disorder, and gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a rare type of tumor that can develop in various parts of the gastrointestinal tract.
The approval encompasses Lanreotide injection in doses of 120 mg/0.5 mL, 90 mg/0.3 mL, and 60 mg/0.2 mL, providing clinicians with versatile treatment options. Cipla’s Lanreotide Injection is deemed an AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) injection, offering a cost-effective alternative for patients.
Lanreotide injection is supplied in single-dose, pre-filled syringes, ready for administration. The approval by USFDA is based on an Abbreviated New Drug Application (NDA), reflecting rigorous evaluation and compliance with regulatory standards.
With Somatuline Depot (Lanreotide) reporting significant sales in the United States, Cipla’s FDA approval paves the way for expanded access to essential treatment options. This milestone underscores Cipla’s commitment to advancing healthcare and addressing unmet medical needs, particularly in the realm of rare diseases and specialized therapies.
